Using different schedules of Temozolomide to treat low grade gliomas: Systematic review of their efficacy and toxicity

Journal of Neuro-Oncology

Volumn 105, Issue 2, 2011, Pages 135-147

  Lashkari, Harsha Prasada ^a   Saso, Srdjan ^b   Moreno, Lucas ^a   Athanasiou, Thanos ^c   Zacharoulis, Stergios ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Children; Low grade gliomas (LGG); Metronomic chemotherapy; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; ANEMIA; BLOOD TOXICITY; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILD; CONSTIPATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GLIOMA; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REVIEW; SCHOOL CHILD; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; GLIOMA; HUMANS; NEOPLASM GRADING;

EID: 82955212768     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0657-7     Document Type: Review

References (51)

1. K Peterson LM DeAngelis 2001 Weighing the benefits and risks of radiation therapy for low-grade glioma Neurology 56 10 1255 1256 11376168 1:STN:280:DC%2BD3M3pt1yqtw%3D%3D (Pubitemid 32455278)
2. TJ Postma M Klein CC Verstappen JE Bromberg M Swennen JA Langendijk MJ Taphoorn P Scheltens BJ Slotman HM van der Ploeg NK Aaronson JJ Heimans 2002 Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma Neurology 59 1 121 123 12105319 1:STN:280:DC%2BD38zmtVOgtQ%3D%3D (Pubitemid 34742806)
3. RJ Packer J Ater J Allen P Phillips R Geyer HS Nicholson R Jakacki E Kurczynski M Needle J Finlay G Reaman JM Boyett 1997 Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas J Neurosurg 86 5 747 754 9126887 10.3171/jns.1997.86.5.0747 1:CAS:528: DyaK2sXms12ht78%3D (Pubitemid 27187674)
4. K Vera L Djafari S Faivre JS Guillamo K Djazouli M Osorio F Parker C Cioloca B Abdulkarim JP Armand E Raymond 2004 Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors Ann Oncol 15 1 161 171 14679137 10.1093/annonc/mdh003 1:STN:280: DC%2BD3srps1KltQ%3D%3D (Pubitemid 38139618)
5. R Nagasubramanian ME Dolan 2003 Temozolomide: realizing the promise and potential Curr Opin Oncol 15 6 412 418 14624222 10.1097/00001622-200311000-00002 1:CAS:528:DC%2BD3sXptVCmsb0%3D (Pubitemid 38147035)
6. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
7. CS Brock ES Newlands SR Wedge M Bower H Evans I Colquhoun M Roddie M Glaser MH Brampton GJ Rustin 1998 Phase I trial of temozolomide using an extended continuous oral schedule Cancer Res 58 19 4363 4367 9766665 1:CAS:528:DyaK1cXmsVyqsbg%3D (Pubitemid 28450038)
8. JC Baer AA Freeman ES Newlands AJ Watson JA Rafferty GP Margison 1993 Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells Br J Cancer 67 6 1299 1302 8512814 10.1038/bjc.1993.241 1:CAS:528:DyaK3sXlvFGht7g%3D (Pubitemid 23172868)
9. SL Gerson 2002 Clinical relevance of MGMT in the treatment of cancer J Clin Oncol 20 9 2388 2399 11981013 10.1200/JCO.2002.06.110 1:CAS:528: DC%2BD38XktVKrsL4%3D (Pubitemid 34441669)
10. RB Khan JJ Raizer MG Malkin KA Bazylewicz LE Abrey 2002 A phase II study of extended low-dose temozolomide in recurrent malignant gliomas Neuro Oncol 4 1 39 43 11772431 1:CAS:528:DC%2BD38XktlGltL4%3D (Pubitemid 34269465)
11. AW Tolcher SL Gerson L Denis C Geyer LA Hammond A Patnaik AD Goetz G Schwartz T Edwards L Reyderman P Statkevich DL Cutler EK Rowinsky 2003 Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 7 1004 1011 12671695 10.1038/sj.bjc. 6600827 1:CAS:528:DC%2BD3sXisFahtrY%3D (Pubitemid 36560766)
12. National Cancer Institute Common Terminology Criteria for Adverse Events (2010) http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference- 5x7.pdf. Accessed 17 June 2011
13. D Moher A Liberati J Tetzlaff DG Altman 2009 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 b2535 19622551 10.1136/bmj.b2535
14. DF Stroup JA Berlin SC Morton I Olkin GD Williamson D Rennie D Moher BJ Becker TA Sipe SB Thacker 2000 Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group JAMA 283 15 2008 2012 10789670 10.1001/jama.283.15.2008 1:STN:280:DC%2BD3c3kvVGgsA%3D%3D (Pubitemid 30214957)
15. The Cochrane Library (2005) Cochrane handbook for systematic reviews of interventions 4.2.5 (updated May 2005)
16. N Mantel W Haenszel 1959 Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 4 719 748 13655060 1:STN:280:DyaG1M%2FosVOhtQ%3D%3D
17. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 3 177 188 3802833 10.1016/0197-2456(86)90046-2 1:STN:280: DyaL2s7gsVamtA%3D%3D (Pubitemid 17189972)
18. Egger M, Smith G, Dg A (1995) Systematic reviews in healthcare: meta-analysis in context. BMJ Books, London
19. RF Galbraith 1988 A note on graphical presentation of estimated odds ratios from several clinical trials Stat Med 7 8 889 894 3413368 10.1002/sim.4780070807 1:STN:280:DyaL1czitFCjtQ%3D%3D
20. S Gururangan MJ Fisher JC Allen JE Herndon JA Quinn DA Reardon JJ Vredenburgh A Desjardins PC Phillips MA Watral JM Krauser AH Friedman HS Friedman 2007 Temozolomide in children with progressive low-grade glioma Neuro Oncol 9 2 161 168 17347491 10.1215/15228517-2006-030 1:CAS:528: DC%2BD2sXltFWgtr4%3D (Pubitemid 46580317)
21. K Hoang-Xuan L Capelle M Kujas S Taillibert H Duffau J Lejeune M Polivka E Criniere Y Marie K Mokhtari AF Carpentier F Laigle JM Simon P Cornu P Broet M Sanson JY Delattre 2004 Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions J Clin Oncol 22 15 3133 3138 15284265 10.1200/JCO.2004.10.169 1:CAS:528:DC%2BD2cXpsVGrs7o%3D (Pubitemid 41103727)
22. S Kesari D Schiff J Drappatz D LaFrankie L Doherty EA Macklin A Muzikansky S Santagata KL Ligon AD Norden A Ciampa J Bradshaw B Levy G Radakovic N Ramakrishna PM Black PY Wen 2009 Phase II study of protracted daily temozolomide for low-grade gliomas in adults Clin Cancer Res 15 1 330 337 19118062 10.1158/1078-0432.CCR-08-0888 1:CAS:528:DC%2BD1MXhs1eqsA%3D%3D
23. N Levin I Lavon B Zelikovitsh D Fuchs F Bokstein Y Fellig T Siegal 2006 Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression Cancer 106 8 1759 1765 16541434 10.1002/cncr.21809 1:CAS:528:DC%2BD28XksFCku7Y%3D
24. R Liu K Solheim MY Polley KR Lamborn M Page A Fedoroff J Rabbitt N Butowski M Prados SM Chang 2009 Quality of life in low-grade glioma patients receiving temozolomide Neuro Oncol 11 1 59 68 18713953 10.1215/15228517-2008-063 1:CAS:528:DC%2BD1MXjtFKnsbY%3D
25. HS Nicholson CS Kretschmar M Krailo M Bernstein R Kadota D Fort H Friedman MB Harris N Tedeschi-Blok C Mazewski J Sato GH Reaman 2007 Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group Cancer 110 7 1542 1550 17705175 10.1002/cncr.22961 1:CAS:528:DC%2BD2sXhtFyqtrbF (Pubitemid 47463069)
26. A Pace A Vidiri E Galie M Carosi S Telera AM Cianciulli P Canalini D Giannarelli B Jandolo CM Carapella 2003 Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response Ann Oncol 14 12 1722 1726 14630675 10.1093/annonc/mdg502 1:STN:280: DC%2BD3srltVWgsw%3D%3D (Pubitemid 38029042)
27. JA Quinn DA Reardon AH Friedman JN Rich JH Sampson JM Provenzale RE McLendon S Gururangan DD Bigner JE Herndon N Avgeropoulos J Finlay S Tourt-Uhlig ML Affronti B Evans V Stafford-Fox S Zaknoen HS Friedman 2003 Phase II trial of temozolomide in patients with progressive low-grade glioma J Clin Oncol 21 4 646 651 12586801 10.1200/JCO.2003.01.009 1:CAS:528:DC%2BD2cXpsVGrur8%3D (Pubitemid 46621898)
28. A Tosoni E Franceschi M Ermani R Bertorelle L Bonaldi V Blatt AA Brandes 2008 Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas J Neurooncol 89 2 179 185 18431544 10.1007/s11060-008-9600-y 1:CAS:528:DC%2BD1cXhtFegu7zF
29. MJ van den Bent MJ Taphoorn AA Brandes J Menten R Stupp M Frenay O Chinot JM Kros CC van der Rijt C Vecht A Allgeier T Gorlia 2003 Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971 J Clin Oncol 21 13 2525 2528 12829671 10.1200/JCO.2003.12.015 (Pubitemid 46606334)
30. MJ van den Bent O Chinot W Boogerd MJ Bravo MJ Taphoorn JM Kros CC van der Rijt CJ Vecht BN De B Baron 2003 Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972 Ann Oncol 14 4 599 602 12649108 10.1093/annonc/mdg157 (Pubitemid 41295090)
31. M Wyss S Hofer M Bruehlmeier M Hefti C Uhlmann E Bartschi UW Buettner U Roelcke 2009 Early metabolic responses in temozolomide treated low-grade glioma patients J Neurooncol 95 1 87 93 19381442 10.1007/s11060-009-9896-2 1:CAS:528:DC%2BD1MXhtFentL3K
32. MC Chamberlain 2008 Temozolomide for recurrent low-grade spinal cord gliomas in adults Cancer 113 5 1019 1024 18615600 10.1002/cncr.23677 1:CAS:528:DC%2BD1cXhtFSlurrO
33. S Everhard G Kaloshi E Criniere A Ouaich-Amiel J Lejeune Y Marie M Sanson M Kujas K Mokhtari K Hoang-Xuan JY Delattre J Thillet 2006 MGMT methylation: a marker of response to temozolomide in low-grade gliomas Ann Neurol 60 6 740 743 17192931 10.1002/ana.21044 1:CAS:528:DC%2BD2sXhsFeqtb8%3D (Pubitemid 46048490)
34. G Kaloshi A ouaich-Amiel F Diakite S Taillibert J Lejeune F Laigle-Donadey MA Renard W Iraqi A Idbaih S Paris L Capelle H Duffau P Cornu JM Simon K Mokhtari M Polivka A Omuro A Carpentier M Sanson JY Delattre K Hoang-Xuan 2007 Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome Neurology 68 21 1831 1836 17515545 10.1212/01.wnl.0000262034.26310.a2 1:CAS:528:DC%2BD2sXltl2itrc%3D (Pubitemid 46791397)
35. SL Khaw LT Coleman PA Downie JA Heath DM Ashley 2007 Temozolomide in pediatric low-grade glioma Pediatr Blood Cancer 49 6 808 811 17588234 10.1002/pbc.21270 (Pubitemid 47519517)
36. DJ Kuo HL Weiner J Wisoff DC Miller EA Knopp JL Finlay 2003 Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas J Pediatr Hematol Oncol 25 5 372 378 12759623 10.1097/00043426-200305000-00005 (Pubitemid 36569968)
37. N Pouratian J Gasco JH Sherman ME Shaffrey D Schiff 2007 Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas J Neurooncol 82 3 281 288 17082887 10.1007/s11060-006-9280-4 1:CAS:528:DC%2BD2sXlvF2ju7c%3D (Pubitemid 46614391)
38. van den Bent MJ, Afra D, de WO, Ben HM, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490):985-990 (Pubitemid 41323034)
39. BG Baumert R Stupp 2008 Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy Ann Oncol 19 Suppl 7 vii217 vii222 18790954 10.1093/annonc/mdn434
40. HS Friedman JP Krischer P Burger WJ Oakes B Hockenberger MD Weiner JM Falletta D Norris AH Ragab DH Mahoney Jr 1992 Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study J Clin Oncol 10 2 249 256 1732426 1:STN:280:DyaK387itF2gtw%3D%3D
41. HS Friedman S Lovell K Rasheed AH Friedman 1998 Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing Committee for The Brain Tumor Center at Duke Med Pediatr Oncol 31 1 16 18 9607424 10.1002/(SICI)1096-911X(199807)31:1<16::AID-MPO3>3.0.CO;2-2 1:STN:280:DyaK1c3mvVCnsg%3D%3D (Pubitemid 28243695)
42. J Glass FH Hochberg ML Gruber DN Louis D Smith B Rattner 1992 The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy J Neurosurg 76 5 741 745 1564535 10.3171/jns.1992.76.5.0741 1:STN:280:DyaK383is1yitQ%3D%3D
43. MD Prados MS Edwards J Rabbitt K Lamborn RL Davis VA Levin 1997 Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen J.Neurooncol 32 3 235 241 9049885 10.1023/A:1005736104205 1:STN:280:DyaK2s3gt1emug%3D%3D (Pubitemid 27077974)
44. J Ater E Holmes T Zhou C Mazewaski W Roberts G Vezina, et al. 2008 Results of COG protocol A9952: a randomised phase 3 study of two chemotherapy regimens for incompletely resected low-grade glioma in young children NeuroOncol 10 451 452
45. ES Newlands MF Stevens SR Wedge RT Wheelhouse C Brock 1997 Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 1 35 61 9189180 10.1016/S0305-7372(97)90019- 0 1:CAS:528:DyaK2sXktFOrt7w%3D (Pubitemid 27273454)
46. R Stupp M Gander S Leyvraz E Newlands 2001 Current and future developments in the use of temozolomide for the treatment of brain tumours Lancet Oncol 2 9 552 560 11905710 10.1016/S1470-2045(01)00489-2 1:CAS:528:DC%2BD3MXntFCnu7s%3D (Pubitemid 33586868)
47. EORTC Brain Tumour Group (2010) Phase III intergroup study of radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with newly diagnosed anaplastic oligodendroglioma or anaplastic mixed glioma with chromosomal co-deletions of 1p and 19q. In: eortc.be (internet), EORTC, Brussels. http://www.eortc.be/protoc/ Details.asp?Protocol=26081&T. EORTC protocol 26081-22086. Accessed 17 June 2011
48. European Organization for Research and Treatment of Cancer (2011) Primary chemotherapy with temozolomide versus radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study. In: ClinicalTrials.gov (internet). National Library of Medicine (US) 2000, Bethesda. http://clinicaltrials.gov/ct2/show/NCT00182819. NLM identifier NCT00182819. Accessed 17 June 2011
49. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta MP (2011). RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 29(15 Suppl): ASCO meeting abstracts:2006
50. Q Zhou P Guo X Wang S Nuthalapati JM Gallo 2007 Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens J Pharmacol Exp Ther 321 1 265 275 17259446 10.1124/jpet.106.118265 1:CAS:528:DC%2BD2sXktVSktrw%3D (Pubitemid 46456967)
51. EL Kreklau C Kurpad DA Williams LC Erickson 1999 Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo J Pharmacol Exp Ther 291 3 1269 1275 10565851 1:CAS:528:DyaK1MXnslynsb8%3D